ATE411341T1 - Einen nmda rezeptor enthaltende multiprotein- komplexe und deren verwendung - Google Patents

Einen nmda rezeptor enthaltende multiprotein- komplexe und deren verwendung

Info

Publication number
ATE411341T1
ATE411341T1 AT01917331T AT01917331T ATE411341T1 AT E411341 T1 ATE411341 T1 AT E411341T1 AT 01917331 T AT01917331 T AT 01917331T AT 01917331 T AT01917331 T AT 01917331T AT E411341 T1 ATE411341 T1 AT E411341T1
Authority
AT
Austria
Prior art keywords
nmda receptor
complexes containing
multiprotein complexes
complexes
methods
Prior art date
Application number
AT01917331T
Other languages
English (en)
Inventor
Seth Garran Niels Grant
Holger Husi
Original Assignee
Univ Edinburgh Inc Under The U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9889219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE411341(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Edinburgh Inc Under The U filed Critical Univ Edinburgh Inc Under The U
Application granted granted Critical
Publication of ATE411341T1 publication Critical patent/ATE411341T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
AT01917331T 2000-04-06 2001-04-06 Einen nmda rezeptor enthaltende multiprotein- komplexe und deren verwendung ATE411341T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008321.2A GB0008321D0 (en) 2000-04-06 2000-04-06 Biological material and uses thereof

Publications (1)

Publication Number Publication Date
ATE411341T1 true ATE411341T1 (de) 2008-10-15

Family

ID=9889219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01917331T ATE411341T1 (de) 2000-04-06 2001-04-06 Einen nmda rezeptor enthaltende multiprotein- komplexe und deren verwendung

Country Status (9)

Country Link
US (1) US20030176651A1 (de)
EP (1) EP1272517B1 (de)
JP (1) JP2003530125A (de)
AT (1) ATE411341T1 (de)
AU (1) AU4441101A (de)
CA (1) CA2405311A1 (de)
DE (1) DE60136170D1 (de)
GB (1) GB0008321D0 (de)
WO (1) WO2001077170A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879621B2 (en) * 2003-05-08 2011-02-01 Phynexus, Inc. Open channel solid phase extraction systems and methods
US20100113563A1 (en) * 2004-01-30 2010-05-06 Zaijie Wang Method for Treating Pain with a Calmodulin Inhibitor
EP1791569A4 (de) * 2004-08-23 2009-12-16 Univ Emory Verbesserte auswahl von ph-abhängigen verbindungen für die in vivo therapie
JP2009503520A (ja) * 2005-07-29 2009-01-29 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ベータアミロイド受容体及びその使用
WO2007115151A2 (en) * 2006-03-31 2007-10-11 Karima Ferrani-Kile Methods and compositions for obtaining and using biologically active multi-protein complexes
WO2014210538A1 (en) * 2013-06-28 2014-12-31 The Regents Of The University Of California Treating cognitive deficits associated with noonan syndrome
CN113354714B (zh) * 2021-07-28 2023-04-28 宋云强 一种广谱抗炎多肽化合物、其制备方法及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2208097A (en) * 1996-03-08 1997-09-22 Regents Of The University Of California, The Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment
GB9611584D0 (en) * 1996-06-04 1996-08-07 Univ Edinburgh Neurotransmitters

Also Published As

Publication number Publication date
EP1272517B1 (de) 2008-10-15
EP1272517A2 (de) 2003-01-08
WO2001077170A3 (en) 2002-03-28
CA2405311A1 (en) 2001-10-18
GB0008321D0 (en) 2000-05-24
WO2001077170A2 (en) 2001-10-18
AU4441101A (en) 2001-10-23
JP2003530125A (ja) 2003-10-14
DE60136170D1 (de) 2008-11-27
US20030176651A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
CY1112458T1 (el) Ενα αντισωμα ειδικο για διαλυτο baff για χρηση στην αντιμετωπιση του καρκινου
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
DK1066380T3 (da) Opløselig T-cellereceptor
DE69732868D1 (de) Mittel gegen Juckreiz
ATE276770T1 (de) Dopamin und serotonin transport-ligande und bilderzeugungsmitteln
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
NO963280L (no) Anvendelse av anti-TNF antistoffer som legemidler i behandling av sykdommer som involverer forhöyede interleukin-6 serumnivåer
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
ES2138977T3 (es) Agonistas muscarinicos.
AP2002002620A0 (en) Substituted arylpyrazines
GT200100008A (es) Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
MXPA05010035A (es) Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
ATE328874T1 (de) Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
EP1463531A4 (de) Verfahren zur hemmung okularer vorgänge
ATE540696T1 (de) Erbb2-antagonisten für die tumorschmerztherapie
ATE343792T1 (de) Diagnostika und therapeutika für maculare degeneration
ATE539768T1 (de) Kombinationen von metabotropische-glutamat- rezeptor-antagonisten und ihre verwendung zur behandlung von suchtstörungen
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
BRPI0412629A (pt) método de tratamento de disfunção ocular em mamìferos
ATE411341T1 (de) Einen nmda rezeptor enthaltende multiprotein- komplexe und deren verwendung
TR200103123T2 (tr) Monofluoroalkil türevleri.
ES2112546T3 (es) Benz(b)azepina-2,5-dionas utiles en el tratamiento de trastornos neurodegenerativos.
TR200100240T2 (tr) Anksiyete bozukluklarının tedavisi
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
DE59709109D1 (de) Monoklonale antikörper gegen einen komplex aus humanem act und einer serinprotease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties